Recombinant Human CCL23 protein (rFc Tag) (HPLC verified)

Species

Human

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg4244

---

Validation Data Gallery

• 

  Purity of Recombinant Human CCL23 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human CCL23 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90%, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CCL23 protein Arg22-Asn120 (Accession# P55773-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 6368
• Accession: P55773-1
• PredictedSize: 38.6 kDa
• SDS-PAGE: 36-45 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

CCL23, or C-C motif chemokine ligand 23, is a protein that belongs to the CC chemokine family, which plays a crucial role in immunoregulation and inflammation. It is one of several chemokine genes clustered on the q-arm of chromosome 17. CCL23 is also upregulated in certain diseases, such as streptococcal soft tissue infection, Staphylococcus aureus bacteremia, and Pneumococcal pneumonia. Additionally, it has been implicated in various types of cancer and is considered a promising biomarker of injury in patients with ischemic conditions.

References:

1.Bonaventura A. et al. (2018) J Intern Med. 283(5):476-478.
2.Kamat K. et al. (2022) Br J Cancer. 127(6):1026-1033.
3.Simats A. et al. (2018) J Intern Med. 283(5):461-475.